Chemistry:Odalasvir

Odalasvir
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name Dimethyl N,N'-(1,4(1,4)-dibenzenacyclohexaphane- 12,42-diylbis{1H-benzimidazole-5,2-diyl[(2S,3aS,7aS)- octahydro-1H-indole-2,1-diyl] [(2S)-3-methyl-1-oxobutan- 1,2-diyl]})biscarbamate;
CAS Number	1415119-52-6 ;
PubChem CID	71474517;
ChemSpider	34500837;
UNII	OVR52K7BDW;
Chemical and physical data
Formula	C60H72N8O6
Molar mass	1001.286 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC;
	InChI InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1; Key:LSYBRGMTRKJATA-IVEWBXRVSA-N;

Short description: Chemical compound

Odalasvir (INN,^[1] previously known as ACH-3102)^[2]^[3] is an investigational new drug in development for the treatment of hepatitis C.^[4] It is an NS5A inhibitor.^[5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.^[6]^[7]^[8] It is under development by Achillion Pharmaceuticals.^{[citation needed]}

References

↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73". World Health Organization. p. 38. https://www.who.int/medicines/publications/druginformation/innlists/RL73_pre.pdf.
↑ "Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. http://www.achillion.com/ACH3102.
↑ "Odalasvir". ChemIDplus. https://chem.nlm.nih.gov/chemidplus/rn/1415119-52-6.
↑ Walker, Tracey (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas.". Managed Healthcare Executive: 47. http://go.galegroup.com/ps/i.do?id=GALE%7CA440401487&v=2.1&it=r&p=GPS&sw=w&asid=711ead20380f089d56147e239e6804ca. Retrieved March 12, 2016.
↑ "Hepatitis C virus NS5A inhibitors and drug resistance mutations". World Journal of Gastroenterology 20 (11): 2902–12. March 2014. doi:10.3748/wjg.v20.i11.2902. PMID 24659881.
↑ "ACH-3102 resources". Achillion Pharmaceuticals. Winter 2011. http://www.achillion.com/ACH3102_resources.
↑ "Achillion gets FDA incentives for hepatitis C drug". 15 May 2012. http://www.businessweek.com/ap/2012-05/D9UP7TCG0.htm.
↑ Levin, Jules (18–22 April 2012). "Preclinical characteristics of ACH-3102". 47th Annual Meeting. Barcelona, Spain: European Association for the Study of the Liver. http://www.natap.org/2012/EASL/EASL_79.htm.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Odalasvir. Read more

[1] "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73". World Health Organization. p. 38. https://www.who.int/medicines/publications/druginformation/innlists/RL73_pre.pdf.

[2] "Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. http://www.achillion.com/ACH3102.

[3] "Odalasvir". ChemIDplus. https://chem.nlm.nih.gov/chemidplus/rn/1415119-52-6.

[4] Walker, Tracey (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas.". Managed Healthcare Executive: 47. http://go.galegroup.com/ps/i.do?id=GALE%7CA440401487&v=2.1&it=r&p=GPS&sw=w&asid=711ead20380f089d56147e239e6804ca. Retrieved March 12, 2016.

[pmid24659881-5] "Hepatitis C virus NS5A inhibitors and drug resistance mutations". World Journal of Gastroenterology 20 (11): 2902–12. March 2014. doi:10.3748/wjg.v20.i11.2902. PMID 24659881.

[6] "ACH-3102 resources". Achillion Pharmaceuticals. Winter 2011. http://www.achillion.com/ACH3102_resources.

[7] "Achillion gets FDA incentives for hepatitis C drug". 15 May 2012. http://www.businessweek.com/ap/2012-05/D9UP7TCG0.htm.

[8] Levin, Jules (18–22 April 2012). "Preclinical characteristics of ACH-3102". 47th Annual Meeting. Barcelona, Spain: European Association for the Study of the Liver. http://www.natap.org/2012/EASL/EASL_79.htm.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Anonymous

Search

Chemistry:Odalasvir

Namespaces

More

Page actions

See also

References

Navigation

Navigation

Help

Translate

Wiki tools

Wiki tools

Legal status

Legal status	US: Investigational New Drug
Identifiers
IUPAC name Dimethyl N,N'-(1,4(1,4)-dibenzenacyclohexaphane- 1²,4²-diylbis{1H-benzimidazole-5,2-diyl[(2S,3aS,7aS)- octahydro-1H-indole-2,1-diyl] [(2S)-3-methyl-1-oxobutan- 1,2-diyl]})biscarbamate
CAS Number	1415119-52-6^Y
PubChem CID	71474517
ChemSpider	34500837
UNII	OVR52K7BDW
Chemical and physical data
Formula	C₆₀H₇₂N₈O₆
Molar mass	1001.286 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChI InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1 Key:LSYBRGMTRKJATA-IVEWBXRVSA-N

Anonymous

Search

Chemistry:Odalasvir

See also

References

Navigation

Wiki tools

Page tools

Other projects

Categories